Dr Reddys Laboratories (RDY) Equity Income (2012 - 2026)

Dr Reddys Laboratories' Equity Income history runs 15 years deep, the most recent figure standing at $503201.4 for Q1 2026.

• In Q1 2026, Equity Income fell 20.77% year-over-year to $503201.4; the TTM figure through Mar 2026 stood at $15831.2 (down 98.63% YoY), while the FY2026 annual figure was -$1.5 million, up 40.87% from the prior year.
• Equity Income was $503201.4 for Q1 2026 at Dr Reddys Laboratories, up from $258277.9 in the prior quarter.
• In the past five years, Equity Income ranged from a high of $2.0 million in Q2 2022 to a low of -$3.1 million in Q1 2024.
• Historically, Equity Income has averaged -$242175.6 across 5 years, with a median of -$1.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Equity Income surged 50807444.1% in 2023, then plunged 211.88% in 2024.
• A 5-year view of Equity Income shows it stood at -$1.0 million in 2022, then jumped by 132.43% to $324267.2 in 2023, then soared by 53.4% to $497435.0 in 2024, then slumped by 48.08% to $258277.9 in 2025, then jumped by 94.83% to $503201.4 in 2026.
• The last three Equity Income figures came in at $503201.4 (Q1 2026), $258277.9 (Q4 2025), and -$722278.7 (Q3 2025), per Business Quant data.